Certain types of biochemical processes can impair the immune system’s ability to recognize and kill cancer cells. Purdue University’s W. Andy Tao and his associates have developed a new way to study these processes. They demonstrated the validity of their method in experiments involving leukemia and rare liver cancer cell lines.

Tao and 10 co-authors published the details of their new method Aug. 1 in the Journal of the American Chemical Society. Their work provides a system for tracking and identifying the various types of proteins and an unheralded but widely secreted class of bioparticles called extracellular vesicles (EVs) that can compromise immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai have developed a powerful new computational tool that could transform how cancer tissues are analyzed and help pave the way for more personalized treatments. The study, published in Nature Biomedical Engineering, introduces MARQO, a next-generation image analysis process that extracts detailed cellular and spatial information from tumor tissue slides with unprecedented accuracy and scalability.Scientists at the Icahn School of Medicine at Mount Sinai have developed a powerful new computational tool that could transform how cancer tissues are analyzed and help pave the way for more personalized treatments. The study, published in Nature Biomedical Engineering, introduces MARQO, a next-generation image analysis process that extracts detailed cellular and spatial information from tumor tissue slides with unprecedented accuracy and scalability.

Researchers at VCU Massey Comprehensive Cancer Center have developed a new computational tool called Vesalius, which could help clinicians understand the complex relationships between cancer cells and their surrounding cells, leading to potential discoveries regarding the development of hard-to-treat cancers. Findings from a new study—published Aug. 21 in Nature Communications—could help guide the identification of predictive biomarkers for multiple cancers and better inform the effectiveness of different treatment options based on individuals’ specific type of disease.

Researchers from the University of Maryland School of Medicine (UMSOM), Brigham and Women’s Hospital in Boston, and other North American institutions, have provided the first technical description for using focused ultrasound to reliably open the blood-brain barrier. The findings, recently published in Device, pave the way for expanding the use of this experimental device to open the blood-brain barrier to improve treatments and diagnostics for patients with brain tumors and other neurological disorders. 

Colorectal cancer (CRC) is a type of cancer that originates in the colon or rectum from precancerous polyps, which can evolve into cancerous growths over time. This review aimed to provide a comprehensive analysis of CRC, its subtypes, clinical manifestations, point-of-care diagnostic approaches, and management strategies. The clinical presentation of CRC often includes symptoms such as blood in stool, changes in bowel habits, abdominal discomfort, weight loss, fatigue, a feeling of incomplete bowel emptying, and anemia. The identification of these signs prompts healthcare professionals to initiate diagnostic measures without delay. Point-of-care diagnosis plays a pivotal role in the early detection of CRC, employing screening tests such as stool tests and colonoscopies. These diagnostic modalities enable healthcare professionals to identify precancerous polyps or early-stage tumors, facilitating timely intervention and significantly improving treatment outcomes. Adherence to screening guidelines is crucial for the prevention and early detection of CRC. Despite advancements in screening and treatment options, there remains a crucial need for more specific, minimally invasive screening methods with minimal side effects. By improving current detection methods, a better screening approach for CRC can be developed. Recent advancements, including single-cell sequencing, spatial transcriptomics, and artificial intelligence integration, hold great promise for enhancing early diagnosis and advancing personalized treatment strategies. Moreover, a healthy lifestyle, including a balanced diet, regular exercise, no tobacco use, and limited alcohol consumption, can significantly lower the risk of CRC. By emphasizing the importance of lifestyle modifications, early screening, and timely intervention, healthcare professionals can significantly reduce the burden of CRC and improve patient outcomes.

Ultrack and inTRACKtive, from scientists at CZ Biohub San Francisco, could shake up how biologists study development, cancer, the immune system, and more